- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals | 2 | Seeking Alpha | ||
| 13.05. | Journey Medical: Starker Gewinn pro Aktie, aber Umsatz enttäuscht | 9 | Investing.com Deutsch | ||
| 13.05. | Transcript: Journey Medical Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 13.05. | Journey Medical: EPS übertrifft Schätzungen um 0,05 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 13.05. | Journey Medical Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 13.05. | Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 201 | GlobeNewswire (Europe) | Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased... ► Artikel lesen | |
| 06.05. | Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 | 2 | GlobeNewswire (USA) | ||
| 21.04. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi | 2 | GlobeNewswire (USA) | ||
| 26.03. | Journey Medical stock rating reiterated at Buy by H.C. Wainwright | 4 | Investing.com | ||
| 26.03. | Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand | 2 | Seeking Alpha | ||
| 25.03. | Journey Medical Non-GAAP EPS of $0.10, revenue of $61.6M misses by $3.05M | 1 | Seeking Alpha | ||
| 25.03. | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | 333 | GlobeNewswire (Europe) | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen | |
| 25.03. | Journey Medical Corp - 8-K, Current Report | 4 | SEC Filings | ||
| 18.03. | Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 | 2 | GlobeNewswire (USA) | ||
| 04.02. | B.Riley reiterates Buy rating on Journey Medical stock, maintains $12 target | 2 | Investing.com | ||
| 08.01. | Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data | 2 | Insider Monkey | ||
| 10.12.25 | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology | 3 | GlobeNewswire (USA) | ||
| 12.11.25 | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 307 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,560 | -0,13 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar belassen. Der Fokus im Onkologieportfolio sei zunächst auf Sigvotatug Vedotin gegen... ► Artikel lesen | |
| GILEAD SCIENCES | 112,28 | +0,30 % | Neue CAR-T-Erfolge bei Autoimmunerkrankungen: Warum Lösungen für Zelltherapien vor dem nächsten Wachstumsschub stehen könnten | ||
| ELI LILLY | 982,20 | -0,05 % | ELI LILLY ist zuletzt auf ein Allzeithoch gestiegen | Der zentrale Auslöser war die neue Erstattungsvereinbarung mit CVS Caremark. Der Pharmacy-Benefit-Manager nimmt die GLP-1-Pille Foundayo ab 1. Juni und die Abnehm-Injektion Zepbound ab 1. Oktober in... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 392,50 | +1,22 % | Vertex Pharmaceuticals Incorporated: Vertex Presents New Data on ALYFTREK at European Cystic Fibrosis Conference | - ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels... ► Artikel lesen | |
| EYEPOINT | 10,200 | 0,00 % | EyePoint, Inc.: EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data | - LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after - - Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 202,00 | -1,94 % | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 207,20 | +0,10 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| OPKO HEALTH | 1,290 | +3,20 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| UNITED THERAPEUTICS | 469,60 | -1,53 % | United Therapeutics Corp Q1 Income Declines | WASHINGTON (dpa-AFX) - United Therapeutics Corp (UTHR) released a profit for first quarter that Dropped, from last yearThe company's bottom line came in at $274.9 million, or $5.82 per share.... ► Artikel lesen | |
| ROYALTY PHARMA | 47,750 | -1,50 % | Royalty Pharma plc - 8-K, Current Report | ||
| CATALYST PHARMACEUTICALS | 27,100 | -0,37 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 59,18 | +0,87 % | BridgeBio Pharma, Inc. - 8-K, Current Report | ||
| TG THERAPEUTICS | 34,500 | +1,17 % | TG Therapeutics: Großer Schritt zum Blockbuster-Medikament | Die Aktie von TG Therapeutics hat nach der Vorlage neuer Studiendaten kräftig zugelegt. Aus Sicht vieler Investoren könnte sich damit die Grundlage für die nächste Wachstumsphase des Biotech-Unternehmens... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 6,675 | +1,60 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers | Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forward Confirmed ORR of 42.9%... ► Artikel lesen | |
| SOLIGENIX | 0,445 | +0,38 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results | PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing... ► Artikel lesen |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 5,970 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.